Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 38   

Articles published

APRI 1.57 -0.06 (-3.68%)
price chart
Cantor Fitzgerald Lowers Apricus Biosciences to Hold (APRI)
Apricus Biosciences Inc logo Cantor Fitzgerald cut shares of Apricus Biosciences (NASDAQ:APRI) from a buy rating to a hold rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.
Investor's Alert: Cliffs Natural Resources Inc (NYSE:CLF), Apricus Biosciences ...
Apricus Biosciences Inc (NASDAQ:APRI) said the U.S. Patent and Trademark Office has issued a notice of allowance for a patent application it submitted related to methods and compositions for treating Raynaud's phenomenon, including claims related to ...
Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application ...
Apricus Biosciences, Inc. APRI, -0.62% a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
Apricus Bioscience Inc.: Apricus Biosciences Announces Notice of Allowance ...  The Wall Street Transcript
Related articles »  
Apricus Biosciences, Inc. (APRI) � Developing Novel Health Solutions
October 3, 2014 (Investorideas.com Newswire) San Diego-based Apricus Biosciences is finding solutions for unmet medical needs.
Forendo Pharma announces the US licensing of fispemifene to Apricus ...
Forendo Pharma Oy, a Karolinska Development AB portfolio company, announced today that it has entered into a definitive agreement to out-license the US development and commercialization rights for fispemifene to Apricus Biosciences Inc. Forendo is ...
Apricus Expands Development Pipeline With the In-Licensing of US Rights for ...  PipelineReview.com (press release)
Related articles »  
Apricus Biosciences Downgraded to Hold at Cantor Fitzgerald (APRI)
Apricus Biosciences Inc logo Apricus Biosciences (NASDAQ:APRI) was downgraded by equities research analysts at Cantor Fitzgerald from a �buy� rating to a �hold� rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.
Apricus Biosciences Director Sandford D. Smith Buys 26500 Shares (APRI)
Apricus Biosciences Inc logo Apricus Biosciences (NASDAQ:APRI) Director Sandford D. Smith acquired 26,500 shares of the company's stock in a transaction dated Thursday, October 23rd.
Related articles »  
Insider Buying: Sandford D. Smith Purchases 26500 Shares of Apricus ...
Apricus Biosciences Inc logo Apricus Biosciences (NASDAQ:APRI) Director Sandford D. Smith purchased 26,500 shares of Apricus Biosciences stock on the open market in a transaction dated Thursday, October 23rd.
Apricus Biosciences Rating Lowered to Hold at Cantor Fitzgerald (APRI)  sleekmoney
Related articles »  
Apricus Biosciences To Present At BIO Investor Forum; Webcast At 2:30 PM ET
(RTTNews.com) - Apricus Biosciences, Inc.( APRI ) will present at the 13th Annual BIO Investor Forum held at the Palace Hotel in San Francisco, CA.
Apricus Biosciences Inc (NASDAQ:APRI) Gets The USPTO Notice Of Allowance ...
Apricus Biosciences Inc (NASDAQ:APRI) said that it had got the Notice of Allowance of its Patent Application submitted to the USPTO.